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Unlocking the full potential of open
innovation in the life sciences through
a classification system
Niclas Nilsson1, nnidk@leo-pharma.com and Timo Minssen2
A common understanding of expectations and requirements is critical for boosting research-driven
business opportunities in open innovation (OI) settings. Transparent communication requires
common definitions and standards for OI to align the expectations of both parties. Here, we suggest a
five-level classification system for OI models, reflecting the degree of openness. The aim of this
classification system is to reduce contract negotiation complexity and times between two parties
looking to engage in OI. Systematizing definitions and contractual terms for OI in the life sciences
helps to reduce entry barriers and boosts collaborative value generation. By providing a contractual
framework with predefined rules, science will be allowed to move more freely, thus maximizing the
potential of OI.
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OI holds much promise as a new business
model for collaborative value creation in the
life sciences [1]. From a corporate perspective,
benefits include faster access to new relevant
technology; the opportunity for biotechs and
small–medium-sized enterprises (SMEs) to
explore new market opportunities; improved
identification of relevant licensing partners;
and boosted value creation. It is no longer
possible to look at innovation as an isolated in-
house event. Instead, creating new value by
innovation has become an increasingly com-
plex process involving knowledge flows across
the entire ecosystem [2]. The need to put such
policies into practice is also acknowledged by
public–private partnerships, such as the In-
novative Medicines Initiative (IMI) exploring1359-6446/ã 2018 The Authors. Published by Elsevier Ltd. This is an o
https://doi.org/10.1016/j.drudis.2018.01.002 new models for collaborations (www.imi.
europa.eu).
OI enables more-efficient dialog between
early- and late-stage research organizations so
that relevant matchmaking can occur more of-
ten, faster, and more easily, by sharing needs for
innovative solutions and reducing traditional
barriers during the exploration phase.
For this to happen, a common understanding
of expectations and requirements is critical for
truly boosting the identification of research-
driven business opportunities. Transparent
communication requires a common definition
and standard for OI, to align the expectations of
both parties.
Here, we suggest a five-level classification
system for OI models, reflecting the degree of
openness. The aim of this classification systempen access article under the CC BY-NC-ND license (http://creativecommis to reduce contract negotiation complexity
and times between two parties looking to
engage in OI, to systematize definitions and
contractual terms for OI in the life science
industry, reducing entry barriers, and boosting
explorative collaborations. This classification
system is derived from the pharmaceutical in-
dustry perspective and the corporations usually
responsible for dictating the legal and business
framework regarding intellectual property (IP)
rights, business terms, conditions, and confi-
dentiality. The need to align the conditions of
interacting under the OI banner comes from an
increasing, but greatly varying, interpretation in
the pharmaceutical industry. The intention is to
provide a starting point for clear and trans-
parent conditions when either providing an OI
platform for the pharmaceutical industry, orons.org/licenses/by-nc-nd/4.0/).
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FIGURE 1
Appearing open for business might be attractive from an outside perspective, but often there are limiting
and greatly varying conditions. To align expectations and fully unleash the powers of open innovation, a
standardized definition of openness is required.
Featu
res
P
ER
SP
EC
TIV
Eengaging with such as a private or public
research institution.
The difference OI can make for life science
and pharmaceutical research
When implemented broadly in the life science
ecosystem, OI allows research knowledge and
technology to flow more easily between parties,
enabling need-based matchmaking. Standard-
ized OI creates a precompetitive infrastructure
that will in turn boost the ability of all parties to
explore opportunities [3]. Sourcing external in-
novation in life sciences often improves the
chances of getting a drug or technology to
market [4].
However, both the perception and the im-
plementation of OI vary greatly and, to avoid
confusion, we suggest a terminology standard
for these types of collaboration [5]. For this, we
need to first define the framework, the language
we use, and the rules of engagement. When the
claim ‘We do OI in life science’ is made, itTABLE 1
Definitions of terminology related to openn
Open terminology in relation
to life science R&D
Brief definition fr
OI Disclosing needs fo
risk and benefits
Open source Methods are open
further developme
Open science Sharing of scientifi
others to explore i
Open access Unbiased access to
exploration of non
Open data Release of scientifi
enabling reanalysis
772 www.drugdiscoverytoday.commust be clear what that entails, from both
perspectives; inbound (seeker, often a larger
pharmaceutical corporation) and outbound
(provider, often a biotech company or a
university). Contractual negotiation is the single-
biggest hurdle when trying to establish a col-
laboration [6], but by providing transparent and
aligned contractual terms for OI, we can spend
less time and fewer resources negotiating con-
tracts, instead focusing on the scientific col-
laboration itself and enabling OI to happen.
Typical questions that might arise in an OI
setting are those related to the contractual
framework, such as: who owns the data
generated (IP rights)? Will a party claim rights
to pursue further (business terms)? Are some
aspects not disclosed (confidentiality or trade
secrets)? Is the proposal subject to scrutiny
before being explored (restraints)? The poten-
tial answers and, hence, the contractual con-
ditions can vary greatly, as can the expectations
when engaging in OI. Although it will beess in life science R&D
om innovation seeker perspective Brief definit
r innovation or problems and sharing Insight to wh
ly shared to enable practical use and
nt by others
Possibility to 
c rationale of strategic interest for
ntellectual overlaps
Identification
 resources allowing external
obvious solutions
Opportunity 
possibilities
c data without restrictions on use, Chance of co
own assetsimpossible for us to delve deeper into legal
details in this short contribution, it is clear that
negotiations can be reduced if a quick
alignment can be established by pointing out
what ‘openness’ in fact refers to when exploring
OI (Fig. 1).
Terminology used when referring to
openness
Although the idea of working openly with ex-
ternal partners is older, the first attempt to
define OI was proposed by Henry Chesbrough in
2003 [7]. The concept of OI is strategic, but the
implementation can be considered an opera-
tional tool or new business model.
To establish a common standard terminolo-
gy, a few frequently used terms must be de-
fined, because they are occasionally used with
different meaning and expectations. These
definitions are based on the perspective that a
larger corporation is seeking innovation by
engaging in collaboration with external part-
ners in OI. A quick definition of each is provided
in Table 1.
So, is it open or not? Here, we suggest that to
be labeled OI, the basic requirement is that
specific details are revealed to a greater extent
than required for traditional outsourcing. This
could refer to disclosure of the problem, or
sharing both the risks and potential benefits.
The general definition of ‘open source’
involves public disclosure of underlying proto-
cols, methods, and processes, which are also
often jointly developed. For pharmaceutical re-
search and development (R&D), the definition
typically refers to full description of the meth-
odology or protocol(s) made available for any-
one to reproduce, copy, or develop. The purpose
is to reach out and create a potential scientific
overlap between two parties, to explore other-
wise nonobvious ideas.ion from innovation provider perspective
at solutions will create value with a partner
develop technology toward tangible value creation
 of relevant science that is of relevance to a partner
to test assets with potential partner exploring new
mbining others’ data sets to increase relevance with
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TABLE 2
Defining levels of openness in life science research collaborations
Degree of openness Disclosing
innovation need
Open access
to resources
Open science,
open source
No terms or
commitment
Open data,
waived rights
Not open – – – – –
Level 1 X – – – –
Level 2 X X – – –
Level 3 X X X – –
Level 4 X X X X –
Level 5 X X X X X
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represents the disclosure of theoretical and
scientific rationale. The purpose is to share un-
derlying science knowledge and grant external
partners access to rationales to facilitate the
identification of intellectual overlaps that could
be jointly explored.
The ability to freely, without cost, retrieve or
use published material, tools, resources, or
knowledge is referred to as ‘Open access’. In a
pharmaceutical R&D setting, ‘open access’ is
proposed to refer to ‘unconditional access to
otherwise and traditionally restricted resources,
tools or knowledge’. The ‘unconditional’ access
should be seen within practical limitations, but
importantly, this removes a biased selection of
how such resources are used by external parties.
‘Open data’ means providing access to, and
use of, generated data that are stored publicly
and are openly available for independent anal-
ysis. For pharmaceutical R&D, ‘open data’ refers
to sharing results and data openly without any
restrictions on use. External partners are invited
to use the results or reanalyze the raw data to
explore new and yet unknown possibilities.
From a practical perspective, it is usually
recommended to apply an open data license
even though the intention is for the data to be in
the public domain. This is to avoid confusion
and make it clear for the user that the data in
fact are available and open for any usage. The
Creative Commons CC Zero (CC0) license is an
example of such an open data license that
waives all rights.
Levels of openness: classification based
on contractual framework
The intention of this classification system is to
provide a reference point of what to expect from
OI, both for seekers and providers of innovation.
The classification system is intended as a
first step towards a standardization, but might
require some modification for broader imple-
mentation. The level going from one to five
should not be seen as the higher the better, butinstead reflects a difference and wider degree of
implemented openness. Also, the reason behind
the use of OI might not require more than, for
example, a third level of openness. A summary
of the five different levels of OI is provided in
Table 2.
Open innovation Level 1: disclosure of
needs with shared risk and benefits
This is the entry level of implementing OI by
allowing external partners insight into an
innovation need or goals, sometimes in the form
of a challenge or a request. Note that more-
traditional external collaborations, such as
contract research, are not classified as OI be-
cause they lack the ‘openness’ from the external
perspective (the solution providers). The differ-
ence, and a critical parameter, for the OI defi-
nition is that some parts or details are openly
disclosed, asking for a solution from an un-
specified party.
Opportunity for innovation seekers include
the identification of new solutions to old pro-
blems, or new theoretical ideas and concepts
that are not restricted or biased to the tradition,
mind-set, culture, capabilities, or history of a
corporation. By contrast, opportunities for in-
novation providers include the possibility to
identify and provide new partners with solutions
that they otherwise would not ask for.
Limitations or risks to this approach include
the isolation of a specific problem or detail
limiting the scope of innovation, or that dis-
closure of details and aims reveals strategic
interest or direction.
An example of OI Level 1 is the challenger
from Novo Nordisk to discover a small-molecule
glucose binder on a third party crowdsourcing
platform (https://www.innocentive.com/ar/
challenge/9933823). The request is for an ex-
ternal party to submit a molecule with docu-
mented effects. The openness is based on the
disclosure of the need for such a solution to-
gether with an invitation to unknown external
parties to participate. The use of third-partyinnovation brokers can increase the chances for
an organization to identify novel solution
opportunities, which is one of the great benefits
of OI for both parties and highlights the dif-
ference from traditional outsourcing.
Open innovation Level 2: open access to
tools, resources, or competencies
In Level 2, the specific OI platform offers
something more to engage with external part-
ners and explore new opportunities. A typical
example is a pharmaceutical company offering
external parties access to specific resources or
assets, such as a collection of molecules. This
effectively creates a (one-way) extension of the
research of the company by allowing others to
explore novel science and opportunities. This
level of openness is regularly accompanied by
an agreement from the external innovation
provider to waive any rights to novel IP. Hence
the provider of the Level 2 OI platform claims the
right to explore possible outcome, often in the
form of first right of refusal.
Opportunities for innovation seekers include
the fact that shelved projects can create value
for someone else, more science and additional
data sets can be generated externally, and new
future collaborations can be seeded. By contrast,
opportunities for innovation providers include
access to unique tools and resources, possibility
to find collaboration opportunities with a new
partner and widen the scope of scientific in-
volvement.
Limitations or risks involve the fact that
avoiding potential disclosure to competitors is
sometimes accomplished by limiting the offered
resources to nonbusiness critical tools. However,
this will also more likely result in new inbound
opportunities that are not relevant. This
becomes a problem if the external party expects
mutual interest.
An example of an OI Level 2 is Eli Lilly’s OI
platform for compound screening (https://
openinnovation.lilly.com/dd/what-we-offer/
screening.html). This resource is freely availablewww.drugdiscoverytoday.com 773
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in undisclosed biological models.
Open innovation Level 3: open science
and open source
The methodology and underlying science is
disclosed so that external parties can suggest
new and relevant opportunities. In addition to
disclosing a request openly (Level 1) and sup-
plying open access to tools for external partners
(Level 2), the third level of OI involves the
detailed disclosure of the science or method-
ology, allowing external partners to fully
understand the underlying rationale of the in-
novation seeker. This is critical if the full po-
tential of OI is to be achieved. Offering
collaborative research tools (Level 2) without
disclosing the science behind can result in novel
opportunities, but only by chance, whereas
Level 3 open science/source ensures that ex-
ternal parties can contribute with rational ideas.
By being more transparent and providing open
science, potential partners can participate in
‘sense making’, which is becoming increasingly
difficult as the amount of external data and
information grows exponentially.
The opportunities for innovation seekers in-
clude the increased chance of unexplored ideas
suggested by independent external parties,
whereas those for innovation providers include
the fact that it will be easier to create a relevant
outreach to a potential partner by under-
standing the science behind value creation.
Limitations or risks involve the fact that sci-
entific information and methodology is often
considered ‘business critical’ and it is thought
that disclosing such information could benefit
competitors. However, by doing so, the potential
gain can be larger in the form of opportunities
that otherwise would not be identified.
An example of an OI Level 3 is AstraZeneca OI
offering access to their clinical compound bank
(https://openinnovation.astrazeneca.com/
preclinical-toolbox.html). Available resources
that are also described in detail add open sci-
ence to this OI model, although there are
business terms with limiting conditions.
Open innovation Level 4: no business
terms or commitment
To encourage participation and reduce the
hurdle of exploring scientific overlaps, it is im-
portant not to impose premature restrictions or
business constraints. Such terms are suited for
work with a predictable outcome, but not to
explore completely novel opportunities. How-
ever, given that being able to patent is often a
critical aspect of the pharma business model,774 www.drugdiscoverytoday.comgiving up business terms is hard because one
effectively relinquishes control. Nevertheless, it
is equally important to realize that, after an
initial and open exploration phase has been
achieved, the continuation can be more tradi-
tional, with confidentiality and patentability.
Opportunities for innovation seekers include
motivating new partners that normally would
not engage. By removing terms, the initial focus
is on creating a joint science-based data set
without spending time and resources on busi-
ness and legal conditions. More, novel, and
diverse opportunities can enter the OI platform
and serendipity can be promoted.
By contrast, opportunities for innovation
providers are similar to those for the seekers:
removing early business terms is an enabling
factor that will allow for exploration of multiple
opportunities. Also, a small company can ex-
plore several opportunities when not being
limited by exclusivity or the first-right-to-nego-
tiate term.
Limitations or risks include the fact that an
external party can walk away from an interesting
opportunity. The worst-case scenario is that
internal resources are spent to create value for a
competitor but the alternative is that the ex-
ternal party would still go to the competitor and
one would not know about it. If this risk is
accepted, the barrier of engagement is signifi-
cantly lowered.
An example of an OI Level 4 is LEO Pharma OI,
where no limiting business terms or acceptance
criteria are applied during the initial exploration
phase and where scientific resources and ra-
tionale are openly disclosed (http://
openinnovation.leo-pharma.com).
Open innovation Level 5: open data
This is the most-advanced model in the degree
of openness. First, to be classified as Level 5, an
OI platform most also exhibit all the features of
Levels 1–4. At this level, the generated data are
made publicly available to all through open
data. This set-up embraces full participation in
the life science ecosystem and can equally
benefit someone external to the partnership.
Both partners must agree to this level of
openness because generated data will be
publicly disclosed and made available without
any restrictions on usage. The fundamental re-
alization is that completely novel and unpre-
dictable innovation will come your way as you
share everything openly. By sharing obstacles,
methods, data, and desires willingly, one max-
imizes the potential and speed of an idea.
Opportunities for innovation seekers include
the fact that full openness maximizes theidentification of nonobvious opportunities and
collaborations to enable orthogonal innovation.
Innovation that you did not even know about or
to ask for, can find its way to you, potentially
creating new value. By contrast, opportunities
for innovation providers include the possibility,
without risk and commitments, to explore
overlapping assets and identify completely new
opportunities to create business value.
As limitations or risks, there will be no, or
limited options for filing patents because new
findings will be public knowledge or obvious.
Anyone can use the generated results, including
competitors. There is no clear return of invest-
ment and no control of IP rights.
Examples of OI Level 5 include the Structural
Genomic Center and the Open Source Malaria
program, which both openly share protocols
and results, inviting others to participate (http://
opensourcemalaria.org). The main driver is the
progression of science and health, not primarily
commercial interests.
Concluding remarks
It is important to realize that all external inno-
vation does not have to be OI. However, when OI
is claimed, it should be clear what it in fact
means, for both parties. As collaborations be-
come increasingly important to advance and
translate research, as well as staying competi-
tive, we need to facilitate how two parties
identify and establish mutual interests. OI is a
business model that utilizes transparency to
allow exploration and increase engagement by
reducing limiting business terms. The degree of
openness is herein suggested to be classified
and aligned across parties for an upfront rec-
ognition of how open an initiative in fact is. With
a joint classification system, fewer resources are
spent on negotiating contracts and more-col-
laborative research can performed.
The suggested definitions are intended as a
first initiative to standardize expectations and
the practical implementation of OI, to boost
exploratory and precompetitive collaborations.
We realize that there are many individual and
specific needs and concerns relating to such
definitions. We also recognize that standardi-
zation might entail risks and that it is not always
the most-feasible way forward where curtailed
solutions are required. Moreover, it is clear that
other important aspects of the innovation
ecosystem, such as business behavior and the
legal frameworks pertaining to IP protection and
governance, and safety regulations, should be
carefully considered and aligned with any
standardization and OI initiatives [8,9]. This also
includes the potential application of emerging
Drug Discovery Today Volume 23, Number 4 April 2018 PERSPECTIVEbig data, artificial intelligence technologies,
smart contracts and blockchain technology.
Hence, we encourage a continued discussion to
further improve the implementation of the
classification system describing the five levels of
openness in life science R&D.
The common classification system for OI in life
sciences will provide a contractual framework
with predefined rules of engagement that will
allow science to move more freely, thus maxi-
mizing our joint potential to improve health and
lives for all.
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